Company
NASDAQ:CRON
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach®, PEACE NATURALS®, and Lord Jones®.
114 stories · page 5 of 6
Crypto leaders hit back against a report from The NY Attorney General’s Office stating the exchanges are subject to manipulation
Physicians practicing within the Canabo Medical Clinic network, which is owned by Aleafia, will lead the study
Left was previously bullish on Tilray but has since changed his tune
The Atlanta-based soft-drinks maker is in talks with Canadian marijuana producer Aurora Cannabis
Fund manager Bruce Campbell tells cannabis investors to expect some ‘scary down days’ and consolidation before ‘the next phase up’
Bob Byrne explains what the company’s transformation as Pyxus International means for cannabis investors
Canada is going to be the first G7 country to legalize cannabis in mid-October
Cannabis stocks had a healthy day on Wednesday, with Tilray shares up significantly, despite negative news from short-seller Andrew Left of Citron Research. Isodiol International shares soared on news from first-quarter earnings results.
Cannabis stocks bounced around on Thursday, with movers including Aphria Inc, which was up 15% after it released news it was exiting the US by completing the sale of its remaining holdings in Liberty Health Sciences Inc
Cannabis stocks continued their rise on Wednesday, most notably, Valens GroWorks, which boosted 48% after it announced four new directors and was given a "buy" rating by analysts at Mackie Research
Canopy Growth jumped to a new high on Tuesday, up 15.4% at C$68.83, making it the 45th biggest company on the Toronto Stock Exchange
The biotech will genetically engineer cannabinoids so that Cronos can bring cannabinoid-based products to market with reliability and scalability
Declaring Tilray too expensive, Left and his team are now taking a short bet against the cannabis stock
Cronos is partnering with Boston-based biotech Gingko Bioworks to develop lab-grown cannabis
Cronos stock recovers on Friday after saner voices intervened and defended the Canadian cannabis stock from a classic short-selling attack
Cannabis stocks tumbled Thursday, most notably, Cronos Group, which dropped 28% after a US short-seller raised concerns the company may have withheld information
The short selling firm calls Cronos the "most overhyped" of all the pot stocks and sets its price target at US$3.50
The Canadian cannabis company entered into a joint venture agreement to begin cultivation in Colombia
Investments and investor services
Unlike most Canadian operators, CannaRoyalty has opted to direct the bulk of its attention in California
The cannabis company entered a joint venture with an affiliate of Colombian agricultural provider Agroidea
